Skip to main content

BRIEF RESEARCH REPORT article

Front. Oncol.
Sec. Hematologic Malignancies
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1432310
This article is part of the Research Topic Transplantation and Cellular Therapy in Lymphomas and Plasma Cell Disorders View all 18 articles

Survival outcomes of patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation in Germany -Real world evidence from an administrative database between 2010 and 2019

Provisionally accepted
Jan-Michel Heger Jan-Michel Heger 1Peter Borchmann Peter Borchmann 1Sybille Riou Sybille Riou 2Barbara Werner Barbara Werner 3Michael S. Papadimitrious Michael S. Papadimitrious 2Jörg Mahlich Jörg Mahlich 2,4*
  • 1 University Hospital of Cologne, Cologne, North Rhine-Westphalia, Germany
  • 2 Miltenyi Biomedicine, Bergisch Gladbach, Germany
  • 3 Team Gesundheit, Essen, Germany
  • 4 University of Vienna, Vienna, Austria

The final, formatted version of the article will be published soon.

    Background: Limited real-world evidence is available for patients with diffuse large B-cell lymphoma (DLBCL) who received an autologous stem cell transplantation (ASCT) in Germany.: To describe real-world survival outcomes of patients with DLBCL who received an ASCT in Germany after diagnosis. Design: A retrospective database study between 2010 and 2019. Methods: Unadjusted overall survival (OS) was plotted by means of the Kaplan-Meier estimator for the overall population and stratified by relapse status. A Cox regression was run to identify factors that influence OS. Results: 112 patients received an ASCT with the average time from first-line treatment to ASCT was 11.7 months. The median OS estimated by Kaplan-Meier was 83.4 months for entire cohort. The only variable that significantly reduced the OS was the presence of subsequent treatment after ASCT in a time-dependent model.OS after ASCT of DLBCL patients in Germany is higher than previously reported and may still be considered a valid option for a carefully selected patients with relapsed/refractory DLBCL.

    Keywords: Diffuse large B-cell lymphoma, Autologous stem cell transplantation, Survival, Real world evidence, claims data, Germany

    Received: 13 May 2024; Accepted: 03 Sep 2024.

    Copyright: © 2024 Heger, Borchmann, Riou, Werner, Papadimitrious and Mahlich. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Jörg Mahlich, University of Vienna, Vienna, Austria

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.